×
S&P 500   3,905.14 (+0.13%)
DOW   31,549.91 (+0.36%)
QQQ   290.85 (-0.55%)
AAPL   140.90 (-0.54%)
MSFT   261.98 (-1.10%)
META   168.66 (-0.49%)
GOOGL   2,279.08 (-1.62%)
AMZN   110.63 (-2.29%)
TSLA   731.61 (-0.43%)
NVDA   165.62 (-1.82%)
NIO   22.71 (-1.05%)
BABA   119.35 (+0.52%)
AMD   83.73 (-2.82%)
MU   59.67 (+1.51%)
CGC   3.71 (-2.11%)
T   20.99 (+1.01%)
GE   67.38 (+1.00%)
F   12.27 (+1.91%)
DIS   100.05 (+3.56%)
AMC   13.82 (-2.19%)
PFE   51.39 (-0.94%)
PYPL   75.18 (-1.00%)
NFLX   187.35 (-0.95%)
S&P 500   3,905.14 (+0.13%)
DOW   31,549.91 (+0.36%)
QQQ   290.85 (-0.55%)
AAPL   140.90 (-0.54%)
MSFT   261.98 (-1.10%)
META   168.66 (-0.49%)
GOOGL   2,279.08 (-1.62%)
AMZN   110.63 (-2.29%)
TSLA   731.61 (-0.43%)
NVDA   165.62 (-1.82%)
NIO   22.71 (-1.05%)
BABA   119.35 (+0.52%)
AMD   83.73 (-2.82%)
MU   59.67 (+1.51%)
CGC   3.71 (-2.11%)
T   20.99 (+1.01%)
GE   67.38 (+1.00%)
F   12.27 (+1.91%)
DIS   100.05 (+3.56%)
AMC   13.82 (-2.19%)
PFE   51.39 (-0.94%)
PYPL   75.18 (-1.00%)
NFLX   187.35 (-0.95%)
S&P 500   3,905.14 (+0.13%)
DOW   31,549.91 (+0.36%)
QQQ   290.85 (-0.55%)
AAPL   140.90 (-0.54%)
MSFT   261.98 (-1.10%)
META   168.66 (-0.49%)
GOOGL   2,279.08 (-1.62%)
AMZN   110.63 (-2.29%)
TSLA   731.61 (-0.43%)
NVDA   165.62 (-1.82%)
NIO   22.71 (-1.05%)
BABA   119.35 (+0.52%)
AMD   83.73 (-2.82%)
MU   59.67 (+1.51%)
CGC   3.71 (-2.11%)
T   20.99 (+1.01%)
GE   67.38 (+1.00%)
F   12.27 (+1.91%)
DIS   100.05 (+3.56%)
AMC   13.82 (-2.19%)
PFE   51.39 (-0.94%)
PYPL   75.18 (-1.00%)
NFLX   187.35 (-0.95%)
S&P 500   3,905.14 (+0.13%)
DOW   31,549.91 (+0.36%)
QQQ   290.85 (-0.55%)
AAPL   140.90 (-0.54%)
MSFT   261.98 (-1.10%)
META   168.66 (-0.49%)
GOOGL   2,279.08 (-1.62%)
AMZN   110.63 (-2.29%)
TSLA   731.61 (-0.43%)
NVDA   165.62 (-1.82%)
NIO   22.71 (-1.05%)
BABA   119.35 (+0.52%)
AMD   83.73 (-2.82%)
MU   59.67 (+1.51%)
CGC   3.71 (-2.11%)
T   20.99 (+1.01%)
GE   67.38 (+1.00%)
F   12.27 (+1.91%)
DIS   100.05 (+3.56%)
AMC   13.82 (-2.19%)
PFE   51.39 (-0.94%)
PYPL   75.18 (-1.00%)
NFLX   187.35 (-0.95%)
NASDAQ:DCPH

Deciphera Pharmaceuticals Stock Forecast, Price & News

$13.76
+0.03 (+0.22%)
(As of 06/28/2022 10:34 AM ET)
Add
Compare
Today's Range
$13.44
$13.98
50-Day Range
$9.11
$13.98
52-Week Range
$6.51
$14.48
Volume
11,010 shs
Average Volume
1.09 million shs
Market Capitalization
$911.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.57
30 days | 90 days | 365 days | Advanced Chart

Receive DCPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Deciphera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

DCPH Stock Forecast (MarketRank)

Overall MarketRank

2.28 out of 5 stars

Medical Sector

291st out of 1,436 stocks

Pharmaceutical Preparations Industry

121st out of 687 stocks

Analyst Opinion: 3.1Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -
Deciphera Pharmaceuticals logo

About Deciphera Pharmaceuticals (NASDAQ:DCPH)

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

DCPH Stock News Headlines

Deciphera Pharmaceuticals Tops Q1 EPS by 10c
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DCPH
Fax
N/A
Employees
280
Year Founded
N/A

Company Calendar

Last Earnings
5/04/2022
Today
6/28/2022
Next Earnings (Estimated)
8/02/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$26.57
High Stock Price Forecast
$70.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+93.1%
Consensus Rating
Hold
Rating Score (0-4)
2.11111111111111
Research Coverage
9 Analysts

Profitability

Net Income
$-299.96 million
Net Margins
-279.96%
Pretax Margin
-284.95%

Debt

Sales & Book Value

Annual Sales
$96.15 million
Book Value
$5.21 per share

Miscellaneous

Free Float
63,502,000
Market Cap
$911.19 million
Optionable
Optionable
Beta
1.40














Deciphera Pharmaceuticals Frequently Asked Questions

Should I buy or sell Deciphera Pharmaceuticals stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last year. There are currently 2 sell ratings, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Deciphera Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DCPH, but not buy additional shares or sell existing shares.
View analyst ratings for Deciphera Pharmaceuticals
or view top-rated stocks.

What is Deciphera Pharmaceuticals' stock price forecast for 2022?

9 equities research analysts have issued 1-year price targets for Deciphera Pharmaceuticals' stock. Their DCPH stock forecasts range from $6.00 to $70.00. On average, they expect Deciphera Pharmaceuticals' stock price to reach $26.57 in the next twelve months. This suggests a possible upside of 93.1% from the stock's current price.
View analysts' price targets for Deciphera Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has Deciphera Pharmaceuticals' stock price performed in 2022?

Deciphera Pharmaceuticals' stock was trading at $9.77 at the beginning of 2022. Since then, DCPH shares have increased by 40.8% and is now trading at $13.76.
View the best growth stocks for 2022 here
.

When is Deciphera Pharmaceuticals' next earnings date?

Deciphera Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Deciphera Pharmaceuticals
.

How were Deciphera Pharmaceuticals' earnings last quarter?

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) posted its quarterly earnings results on Wednesday, May, 4th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.83) by $0.03. The company earned $29.22 million during the quarter, compared to analyst estimates of $27.17 million. Deciphera Pharmaceuticals had a negative net margin of 279.96% and a negative trailing twelve-month return on equity of 79.96%. The firm's quarterly revenue was up 16.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.06) earnings per share.
View Deciphera Pharmaceuticals' earnings history
.

Who are Deciphera Pharmaceuticals' key executives?

Deciphera Pharmaceuticals' management team includes the following people:
  • Mr. Steven L. Hoerter, Pres, CEO & Director (Age 51, Pay $1.01M)
  • Dr. Daniel L. Flynn Ph.D., Exec. VP, Chief Scientific Officer & Founder (Age 67, Pay $645.61k)
  • Mr. Thomas Patrick Kelly J.D., Exec. VP, CFO & Treasurer (Age 51, Pay $644.12k) (LinkedIn Profile)
  • Mr. Daniel C. Martin, Sr. VP & Chief Commercial Officer (Age 47, Pay $611.24k)
  • Dr. Matthew L. Sherman M.D., Exec. VP & Chief Medical Officer (Age 66, Pay $725.85k)
  • Dr. Stephen B. Ruddy Ph.D., Sr. VP & Chief Technical Officer (Age 58)
  • Ms. Jennifer Robinson, VP of Investor Relations
  • Mr. Jeffrey M. Held J.D., Sr. VP & Gen. Counsel
  • Ms. Jama Pitman, Sr. VP of Regulatory, Quality & Portfolio Management (Age 43)
  • Ms. Margarida Duarte, Sr. VP & Head of International

What is Steve Hoerter's approval rating as Deciphera Pharmaceuticals' CEO?

3 employees have rated Deciphera Pharmaceuticals CEO Steve Hoerter on Glassdoor.com. Steve Hoerter has an approval rating of 100% among Deciphera Pharmaceuticals' employees. This puts Steve Hoerter in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Deciphera Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include NVIDIA (NVDA), Ionis Pharmaceuticals (IONS), Vertex Pharmaceuticals (VRTX), Allena Pharmaceuticals (ALNA), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Iovance Biotherapeutics (IOVA), SCYNEXIS (SCYX), Axsome Therapeutics (AXSM) and Exelixis (EXEL).

When did Deciphera Pharmaceuticals IPO?

(DCPH) raised $101 million in an initial public offering on Thursday, September 28th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

What is Deciphera Pharmaceuticals' stock symbol?

Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."

Who are Deciphera Pharmaceuticals' major shareholders?

Deciphera Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include State Street Corp (8.67%), BlackRock Inc. (7.32%), Vanguard Group Inc. (5.43%), Federated Hermes Inc. (2.96%), Assenagon Asset Management S.A. (1.46%) and Goldman Sachs Group Inc. (1.21%). Company insiders that own Deciphera Pharmaceuticals stock include Brightstar Associates Llc, Christopher John Morl, Daniel C Martin, Daniel Lee Flynn, Jama Pitman, James Arthur Bristol, Matthew L Sherman, Michael Douglas Taylor, New Leaf Venture Management Ii, Patricia L Allen and Thomas Patrick Kelly.
View institutional ownership trends for Deciphera Pharmaceuticals
.

Which institutional investors are selling Deciphera Pharmaceuticals stock?

DCPH stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Bank of America Corp DE, State Street Corp, Citigroup Inc., Acadian Asset Management LLC, Wellington Management Group LLP, UBS Group AG, and Charles Schwab Investment Management Inc.. Company insiders that have sold Deciphera Pharmaceuticals company stock in the last two years include Daniel Lee Flynn, Jama Pitman, James Arthur Bristol, Matthew L Sherman, Michael Douglas Taylor, and Thomas Patrick Kelly.
View insider buying and selling activity for Deciphera Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Deciphera Pharmaceuticals stock?

DCPH stock was acquired by a variety of institutional investors in the last quarter, including Federated Hermes Inc., BlackRock Inc., Assenagon Asset Management S.A., PDT Partners LLC, Pinz Capital Management LP, Vanguard Group Inc., Connor Clark & Lunn Investment Management Ltd., and Panagora Asset Management Inc..
View insider buying and selling activity for Deciphera Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Deciphera Pharmaceuticals?

Shares of DCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Deciphera Pharmaceuticals' stock price today?

One share of DCPH stock can currently be purchased for approximately $13.76.

How much money does Deciphera Pharmaceuticals make?

Deciphera Pharmaceuticals (NASDAQ:DCPH) has a market capitalization of $911.19 million and generates $96.15 million in revenue each year. The company earns $-299.96 million in net income (profit) each year or ($4.89) on an earnings per share basis.

How many employees does Deciphera Pharmaceuticals have?

Deciphera Pharmaceuticals employs 280 workers across the globe.

How can I contact Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals' mailing address is 200 SMITH STREET, Waltham MA, 02451. The official website for Deciphera Pharmaceuticals is www.deciphera.com. The company can be reached via phone at (781) 209-6400 or via email at [email protected].

This page (NASDAQ:DCPH) was last updated on 6/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected]rketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.